The FDA has approved Inluriyo (imlunestrant), an oral therapy for advanced breast cancer that targets estrogen receptor-1 mutations. A phase 3 clinical trial found that patients receiving the treatment had improved progression-free survival compared to those on a different investigational regimen.

A recent phase 3 study shows that combining the targeted therapy osimertinib with chemotherapy may revolutionize treatment for patients with advanced EGFR-mutated lung cancer. Investigators report unprecedented survival rates, sparking optimism for significantly improved outcomes in this patient group.